• Markets
  • icon
  • Companies
ALA · ASX

Arovella Therapeutics Limited (ASX:ALA)

AU$0.12

 -0.005 (-4.167%)
ASX:Live
17/05/2024 04:10:34 PM
Hammer Bearish HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

ALA Overview

ALA Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ALA

Telephone

Address

Description

Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. Its technologies include iNKT cell therapy, CAR19-iNKT + CF33-CD19, CLDN18.2-iNKT, and DKK1-CAR-iNKT. The company was founded on December 21, 1999 and is headquartered in Carlton South, Australia.

ALA Price Chart

Key Stats

Market Cap

AU$126.02M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.04 - 0.19

Trade Value (12mth)

AU$55,185.00

1 week

-8%

1 month

9.52%

YTD

-4.17%

1 year

91.67%

All time high

14.779800415039062

Key Fundamentals

EPS 3 yr Growth

-75.800%

EBITDA Margin

N/A

Operating Cashflow

-$5m

Free Cash Flow Return

N/A

ROIC

N/A

Interest Coverage

N/A

Quick Ratio

N/A

Other Data

Shares on Issue (Fully Dilluted)

901m

HALO Sector

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ALA Announcements

Latest Announcements

Date Announcements

01 May 24

Updated Share Trading Policy

×

Updated Share Trading Policy

30 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

23 April 24

Notice of Extraordinary General Meeting/Proxy Form

×

Notice of Extraordinary General Meeting/Proxy Form

23 April 24

Proposed issue of securities - ALA

×

Proposed issue of securities - ALA

10 April 24

Notification regarding unquoted securities - ALA

×

Notification regarding unquoted securities - ALA

09 April 24

Arovella presents ALA-101 data at AACR

×

Arovella presents ALA-101 data at AACR

04 April 24

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

04 April 24

Notice Under Section 708A

×

Notice Under Section 708A

03 April 24

Change of Director's Interest Notice - GP

×

Change of Director's Interest Notice - GP

03 April 24

Prof Gianpietro Dotti appointed to Scientific Advisory Board

×

Prof Gianpietro Dotti appointed to Scientific Advisory Board

02 April 24

Change of Director's Interest Notice - TD

×

Change of Director's Interest Notice - TD

28 March 24

Change of Director's Interest Notice - MB

×

Change of Director's Interest Notice - MB

27 March 24

Arovella to present at AACR annual meeting

×

Arovella to present at AACR annual meeting

26 March 24

Arovella Completes $12.5M Placement - Funded to Phase 1 Data

×

Arovella Completes $12.5M Placement - Funded to Phase 1 Data

26 March 24

Proposed issue of securities - ALA

×

Proposed issue of securities - ALA

26 March 24

Proposed issue of securities - ALA

×

Proposed issue of securities - ALA

26 March 24

Investor Presentation

×

Investor Presentation

22 March 24

Pause in Trading

×

Pause in Trading

22 March 24

Trading Halt

×

Trading Halt

20 March 24

ALA-101 and onCARlytics collaboration update

×

ALA-101 and onCARlytics collaboration update

20 March 24

NWR Virtual Healthcare Conference Presentation

×

NWR Virtual Healthcare Conference Presentation

19 March 24

Arovella to present at NWR virtual healthcare conference

×

Arovella to present at NWR virtual healthcare conference

14 March 24

Spark Plus Singapore Healthcare Day Presentation

×

Spark Plus Singapore Healthcare Day Presentation

01 March 24

Release of Shares from Escrow

×

Release of Shares from Escrow

29 February 24

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

ALA Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.02 -0.02 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.02 -0.02 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 74.3 -3.3 8.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.01 N/A Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.01 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 68.2 -44.1 N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock -19.7 -49.9 N/A Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.02 0.01 N/A Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.01 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 1,930.6 -36.6 N/A Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 331 550 N/A Lock Lock Lock
Basic m Lock Lock Lock Lock 331 550 N/A Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -51.7 14.9 37.2 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 3 5 4 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -2 -2 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock -19.2 -23.0 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock -747.6 -800.0 N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 848 900 N/A Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -4 -7 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 4.2 -74.6 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,568.2 -2,381.6 N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -5 -8 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 2.0 -62.0 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,821.6 -2,568.0 N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -6 -9 N/A Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 0 N/A Lock Lock Lock
Net Income $m Lock Lock Lock Lock -5 -9 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock 49.2 -70.8 -18.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,961.3 -2,914.2 -2,508.4 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -4 -6 -5 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 -1 N/A Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 10 6 N/A Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -4 -6 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.7 -69.9 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock -14.4 -21.3 N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 7 6 N/A Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 11 9 N/A Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -7 -6 0 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 2 N/A Lock Lock Lock
Equity $m Lock Lock Lock Lock 9 8 2 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 9 8 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 117.0 -14.4 N/A Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -47.2 -93.6 N/A Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -56.2 -113.2 -557.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -70.6 -90.3 N/A Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -76.9 -103.4 N/A Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -54.0 -75.2 N/A Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -121.2 -36.2 N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.6 0.8 N/A Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -73.9 -77.8 -7.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 4.3 4.4 N/A Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 4.3 4.4 N/A Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 91.5 92.2 N/A Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -209.1 -415.5 -312.4 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.3 1.0 N/A Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 200.1 N/A N/A Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.1 N/A Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 88.4 254.2 N/A Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 N/A Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 N/A Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -2,207.1 -2,914.2 N/A Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -53.1 -93.6 N/A Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -47.2 -93.6 N/A Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.2 N/A Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -56.2 -113.2 -557.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 N/A Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -56.2 -113.2 N/A Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 1.8 N/A N/A Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 1,080.6 352.0 N/A Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 1,082.4 352.0 N/A Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 81.1 67.1 N/A Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 1,001.3 284.9 N/A Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ALA Shortsell

Frequently Asked Questions

The current share price of Arovella Therapeutics Limited (ALA:ASX) is AU$0.12.
The 52-week high share price for Arovella Therapeutics Limited (ALA:ASX) is AU$0.19.
The 52-week low share price for Arovella Therapeutics Limited (ALA:ASX)? is AU$0.04.
Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.
Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.
Arovella Therapeutics Limited (ALA:ASX) has a franking level of 0.0%.
Arovella Therapeutics Limited (ALA:ASX) is classified in the Healthcare.
The current P/E ratio for Arovella Therapeutics Limited (ALA:ASX) is .